Skip to main content
Premium Trial:

Request an Annual Quote

Regulus Licenses miRNA-Modulation Inventions from CalTech

Premium

Regulus Therapeutics, the microRNA drug joint venture of Alnylam Pharmaceuticals and Isis Pharmaceuticals, said this week that it has exclusively licensed California Institute of Technology inventions related to the modulation of miR-146 and miR-155, key mediators of the inflammatory response.

According to the company, miR-155 has been found to be induced during the macrophage inflammatory response and is a common target of a broad range of inflammatory mediators. "As miR-155 is known to function as an oncogene, these observations suggest a link between inflammation and cancer," Regulus noted.

Meanwhile, miR-146 "is induced, in an NF-kB-dependent manner, in response to proinflammatory mediators," the company added. "These findings suggest that modulation of miR-146 may be of therapeutic benefit in treating diseases characterized by excessive activation of innate immunity signaling."

The Scan

More Boosters for US

Following US Food and Drug Administration authorization, the Centers for Disease Control and Prevention has endorsed booster doses of the Moderna and Johnson & Johnson SARS-CoV-2 vaccines, the Washington Post writes.

From a Pig

A genetically modified pig kidney was transplanted into a human without triggering an immune response, Reuters reports.

For Privacy's Sake

Wired reports that more US states are passing genetic privacy laws.

Science Paper on How Poaching Drove Evolution in African Elephants

In Science this week: poaching has led to the rapid evolution of tuskless African elephants.